Recombination is one of the major sources of genetic variation in viruses. RNA viruses, such as rabbit hemorrhagic disease virus (RHDV), are among the viruses with the highest recombination rates. Several recombination events have been described for RHDV, mostly as a consequence of their genomic architecture. Here, we undertook phylogenetic and recombination analyses of French and Swedish RHDV strains from 1994 to 2016 and uncovered a new intergenotypic recombination event. This event occurred in the late 1990s/early 2000s and involved nonpathogenic GI.3 strains as donors for the nonstructural part of the genome of these recombinants, while pathogenic GI.1d strains contributed to the structural part. These GI.3P–GI.1d recombinant strains did not entirely replace GI.1d (nonrecombinant) strains, but became the dominant strains in France and Sweden, likely due to a fitness advantage associated with this genomic architecture. GI.3P–GI.1d (P stands for polymerase) strains persisted until 2013 and 2016 in Sweden and France, respectively, and cocirculated with the new genotype GI.2 in France. Since strains from the first GI.2 outbreaks were GI.3P–GI.2, we hypothesize that GI.3P–GI.1d could be the parental strain. Our results confirm the outstanding recombination ability of RHDV and its importance in the evolution of lagoviruses, which was only revealed by studying complete genomic sequences.
1 August 2020 in Infection, Genetics and Evolution
First recognized as highly pathogenic viruses, hare lagoviruses belonging to genotype GII.1 (EBHSV) infect various Lepus species. Genetically distinct benign lagoviruses (Hare Calicivirus, HaCV) have recently been identified but few data have been available so far on these strains. The analysis of 199 samples from hunted hares collected throughout France allowed the detection of 20 HaCV and showed that they were widely distributed in this country. Ten HaCV capsid protein gene sequences were characterized. A first HaCV capsid protein structural model was proposed, revealing a global structure similar to that of a pathogenic GII.1 strain. The HaCV sequences showed an even higher genetic diversity than previously appreciated, with the characterization of two genotypes (GII.2, GII.3) and several additional putative genotypes. The most recent common ancestor for HaCV VP60 gene was estimated to be much older than that for GII.1 pathogenic strains. These results give new insights into the phylogenetic relationships of HaCV within the Lagovirus genus.
Background: Rabbit haemorrhagic disease virus Lagovirus europaeus/GI.1d variant (GI.1d/RHDV) was identified in 1990 in France, and until the emergence of the new genotype GI.2, it was the main variant circulating in the country. The early stages of RHDV infection have been described in a few studies of rabbits experimentally infected with earlier strains, but no information was given on the minimum infective dose. We report the genomic and phenotypic characterisation of a GI.1d/RHDV strain collected in 2000 in France (GI.1d/00–21). Results: We performed in vivo assays in rabbits to study virus replication kinetics in several tissues at the early stage of infection, and to estimate the minimum infective dose. Four tested doses, negligible (10− 1 viral genome copies), low (104), high (107) and very high (1011) were quantified using a method combining density gradient centrifugation of the viral particles and an RT-qPCR technique developed to quantify genomic RNA (gRNA). The GI.1d/00–21 genome showed the same genomic organisation as other lagoviruses; however, a substitution in the 5′ untranslated region and a change in the potential p23/2C-like helicase cleavage site were observed. We showed that the liver of one of the two rabbits inoculated via the oral route was infected at 16 h post-infection and all tissues at 39 h post-infection. GI.1d/00–21 induced classical RHD signs (depression) and lesions (haemorrhage and splenomegaly). Although infective dose estimation should be interpreted with caution, the minimum infective dose that infected an inoculated rabbit was lower or equal to 104 gRNA copies, whereas between 104 and 107 gRNA copies were required to also induce mortality. Conclusions: These results provide a better understanding of GI.1d/RHDV infection in rabbits. The genome analysis showed a newly observed mutation in the 5′ untranslated region of a lagovirus, whose role remains unknown. The phenotypic analysis showed that the pathogenicity of GI.1d/00–21 and the replication kinetics in infected organs were close to those reported for the original GI.1 strains, and could not alone explain the observed selective advantage of the GI.1d strains. Determining the minimum dose of viral particles required to cause mortality in rabbits is an important input for in vivo studies.
Viral respiratory infections remain a major and recurrent public health threat. Among them, influenza viruses are responsible for ⁓500,000 deaths worldwide and a high economic burden. The recurrent threat of emerging zoonotic or pandemic viruses worsens this scenario, being SARS-CoV-2 and the millions of COVID-19 deaths the most recent example. The rapid evolution of circulating influenza and SARS-CoV-2 viruses allows the emergence and dissemination of variant strains carrying mutations resulting in suboptimal vaccine protection and/or reduced efficacy of current limited therapeutic arsenal. In this context, host-targeted approaches constitute a promising antiviral strategy aiming to achieve broad-spectrum activity and mitigate the emergence of viral resistance against classic direct acting antivirals. Here, we demonstrated that diltiazem, a calcium channel blocker currently used to treat angor, induces an ISG expression profile characteristic of an antiviral cellular state mainly driven by IFN-λ. We then evaluated the potential of the diltiazem-baloxavir combination against Influenza A wild-type and the PA I38T resistant strain in cell culture and human airway epithelia (HAE). We analogously evaluated the diltiazem-molnupiravir combination against SARS-CoV-2, including variants of concern. Our results demonstrate the broad-spectrum antiviral activity of diltiazem against Influenza A viruses, including resistant strains, as well as the capacity to potentiate the antiviral effect of baloxavir. The diltiazem-molnupiravir combination further reduced viral production and protected the integrity of HAE infected with SARS-CoV-2. This study highlights the major interest of combining direct acting and host-targeted agents as a promising strategy against circulating and emerging viruses.
Background: The COVID‐19 pandemic has underscored the critical role of indoor air quality and ventilation in the transmission of respiratory viruses. Although portable air cleaners (PACs) have proliferated in recent years, most performance evaluations rely on indirect measurement approaches or surrogate microorganisms, leaving uncertainty regarding their true efficacy against infectious human bioaerosols. Objectives: We aimed to develop and validate a highly controlled test bench for comprehensive evaluation of PACs in accordance with evolving standards, incorporating infectious respiratory human pathogens, spectrometric analysis under realistic environmental conditions, and computational fluid dynamics (CFD) supporting experimental design and interpretation of airflow patterns. Methods: The experimental platform consists of a 20 m 3 BSL‐3 chamber equipped for precise control of airflow, humidity, and temperature, allowing nebulization of infectious viruses (SARS‐CoV‐2, influenza A/H1N1pdm09, and adenovirus), bacteria ( Staphylococcus aureus ), and fungi ( Aspergillus fumigatus ). Natural decay rates and stabilities were characterized for each microorganism in homogeneous, highly contaminated atmospheres. The performance of a HEPA H14 PAC (Camfil City M) was evaluated under varying positions (center/corner) and airflow scenarios, with additional interference simulated by open‐window ventilation. Air samples were analyzed by TCID50 assays and particle spectrometry. Results: Stable contaminated atmospheres were reproducibly generated, with airborne concentrations remaining stable for at least 1 h. S. aureus exhibited the greatest stability, while adenovirus and influenza A decayed more rapidly. PAC efficacy depended on device placement and ventilation conditions, with synergistic effects observed when combining air filtration and ventilation. Experimental decay rates for infectious virus and aerosols consistently exceeded CFD predictions, likely due to modelling limitations. Conclusions: This study presents an advanced methodology for evaluating PAC performance against infectious airborne pathogens under realistic, variable environmental conditions. The findings underscore the importance of considering infectious bioaerosol dynamics, device placement, and airflow characteristics when assessing PAC effectiveness and highlight the limitations of solely modelling inert particles in CFD analyses.
Les lagovirus infectent les léporidés (lapins et lièvres). Les lagovirus pathogènes tels que le Rabbit haemorragic disease virus (RHDV) et l’European Brown Hare Syndrome virus (EBHSV) provoquent des hépatites virales souvent mortelles ayant de graves conséquences économiques et écologiques. Les lagovirus non-pathogènes tels que les European Rabbit Calicivirus 1 et 2 (RCV-E1 et RCV-E2) et les Hare Calicivirus (HaCV) ne provoquent aucune maladie chez les lapins et les lièvres, respectivement. L’émergence d’un nouveau lagovirus pathogène en 2010, nommé RHDV2, capable d’infecter à la fois les lapins et les lièvres, nous a poussé à nous interroger sur l’origine de la pathogénicité chez les lagovirus. L’hypothèse étudiée est l’évolution de souches non-pathogènes vers des souches pathogènes. Pour cela, la diversité génétique des lagovirus non-pathogènes, peu connue chez le lièvre, a été étudiée chez cette espèce. Onze nouvelles séquences de gène codant la protéine de capside et la première séquence du génome complet d’un virus HaCV ont été obtenues. Ces données ont montré la grande diversité génétique des HaCV et leur circulation bien avant la première détection des EBHSV en 1980. Toutefois, aucun lien évolutif n’a été trouvé avec les EBHSV. De nouvelles séquences de génomes complets ou de régions codantes de RCV-E1 et de RHDV2 ont aussi été caractérisées. Les analyses génétiques ont suggéré qu’un évènement de recombinaison entre un virus RCV-E1 et un virus inconnu était à l’origine de l’émergence des RHDV2. Dans la seconde partie de la thèse, nous avons tenté de développer un nouveau système de génétique inverse (GI) pour le RHDV afin d’étudier les bases moléculaires du pouvoir pathogène. Le génotype et le phénotype in vivo d’une souche RHDV de référence ont été caractérisés, puis des essais de régénération de cette souche en GI ont été effectués in vitro et in vivo pour valider le système en cours de développement. Les résultats obtenus ont montré que le système était capable de produire de l’ARN viral et la protéine de capside in vitro. Les essais in vivo visant à régénérer le virus n’ont pas permis l’infection de lapins. Cependant, la majorité des animaux ont séroconverti. Ces résultats n’ont pas permis de conclure que le système de GI était capable de produire des particules virales infectieuses et des points d’amélioration sont proposés.